Yale Cancer Center Smilow Cancer Hospital - Episode 1

Yale Cancer Center Merges Cutting Edge Research with Personalized Medicine

Now Viewing
EP. 1: Yale Cancer Center Merges Cutting Edge Research with Personalized Medicine
EP. 2: Dr. Decker on Pembrolizumab With Concurrent Chemoradiotherapy in Inoperable Locally Advanced NSCLC
EP. 3: Dr. Anees Chagpar Named 2021 ASCO Fellow
EP. 4: Yale Cancer Center’s Dr. Lieping Chen Elected to Prestigious National Academy of Sciences
EP. 5: Yale Research to be Presented at 2021 ASCO Annual Meeting
EP. 6: Dr. Bewersdorf on the Role of Allogeneic Transplant in Myelofibrosis
EP. 7: Barbara Burtness Named Interim Associate Director for Diversity, Equity, and Inclusion at Yale Cancer Center
EP. 8: Joseph W. Kim Receives Prestigious 2021 Cancer Clinical Investigator Team Leadership Award
EP. 9: Yale Cancer Center Perspective Highlights New Advances for NSCLC
EP. 10: Yale Cancer Center Study Shows Stem-Like T Cells Could Aid Immunotherapy in Cancer Treatment
EP. 11: Dr. Silber on the Importance of Improving Clinical Trial Inclusivity in Breast Cancer
EP. 12: Dr. Lustberg Discusses Ongoing Research in Breast Cancer
EP. 13: Margaret Gilshannon named Deputy Director for Finance & Administration at Yale Cancer Center
EP. 14: Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs
EP. 15: Eric P. Winer to lead Yale Cancer Center and Smilow Cancer Hospital
EP. 16: Dr. Parker Discusses the Importance of Optimizing Treatment in Multiple Myeloma
EP. 17: Yale Cancer Center Study Shows New Strategy to Boost Immune System to Fight Melanoma
EP. 18: Dr. Fernandez on the Need to Refine Immunohistochemistry Testing in HER2+ Breast Cancer
EP. 19: Dr. Fernandez on the Utility of Trastuzumab Deruxtecan in HER2-Low Breast Cancer
EP. 20: Immunotherapy Advances Drive Progress in Lung Cancer Treatment
EP. 21: Ian E. Krop, MD, PhD, Named Chief Clinical Research Officer, Associate Cancer Center Director for Clinical Research at Yale Cancer Center
EP. 22: Yale Cancer Center Study Reveals Disparities in Telemedicine Use in Patients with Hematologic Cancers
EP. 23: Addition of Bevacizumab to Ixabepilone Is Effective, Tolerable in Platinum-Resistant Ovarian Cancer
EP. 24: Dr. Petrylak on the Rationale of the EV-103 Trial in MIBC
EP. 25: Yale Cancer Center and School of Public Health Receive Grant to Study Lifestyle Intervention in Women with Ovarian Cancer
EP. 26: Berzosertib Plus Standard Chemoradiation Elicits Promising Responses in Locally Advanced HNSCC
EP. 27: Barbara Burtness Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital
EP. 28: Expert Insights on First-line Treatment Strategies in SCLC
EP. 29: Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC
EP. 30: ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC
EP. 31: Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%
EP. 32: Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC
EP. 33: Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy
EP. 34: Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond
EP. 35: LAGOON and IMFORTE Trials: Data Updates and Expert Insights
EP. 36: 2L Dosing Considerations and Management Strategies for SCLC
EP. 37: Novel Treatment Approaches for SCLC and Future Perspectives